Spiroketal derivatives, compositions containing them and their use as
therapeutic agents
    1.
    发明授权
    Spiroketal derivatives, compositions containing them and their use as therapeutic agents 失效
    螺缩酮衍生物,含有它们的组合物及其作为治疗剂的用途

    公开(公告)号:US5728695A

    公开(公告)日:1998-03-17

    申请号:US849969

    申请日:1997-06-20

    CPC分类号: C07D498/10

    摘要: The present invention relates to spiroketal derivatives of formula (I) and pharmaceutically acceptable salts thereof wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.9a, R.sup.9b, m and n are as defined in the specification, and to processes for their preparation, to intermediates used in their synthesis, to pharmaceutical compositions containing them, and to their use in therapy. The compounds are of particular use in the treatment or prevention of pain, inflammation, migraine, emesis and postherpetic neuralgia. ##STR1##

    摘要翻译: PCT No.PCT / GB95 / 02927 Sec。 371日期:1997年6月20日 102(e)日期1996年6月20日PCT 1995年12月15日PCT PCT。 公开号WO96 / 20197 日本时间1996年7月4日本发明涉及式(I)的螺缩酮衍生物及其药学上可接受的盐,其中R1,R2,R3,R4,R5,R6,R9a,R9b,m和n如说明书中所定义, 其制备方法,其合成中使用的中间体,含有它们的药物组合物及其在治疗中的用途。 该化合物特别用于治疗或预防疼痛,炎症,偏头痛,呕吐和带状疱疹后神经痛。 (一)

    Morpholine derivatives, compositions containing them and their use as
therapeutic agents
    4.
    发明授权
    Morpholine derivatives, compositions containing them and their use as therapeutic agents 失效
    吗啉衍生物,含有它们的组合物及其作为治疗剂的用途

    公开(公告)号:US5877316A

    公开(公告)日:1999-03-02

    申请号:US913566

    申请日:1997-09-16

    CPC分类号: C07D413/06

    摘要: The present invention relates to compounds of formula (I), wherein R.sup.1 and R.sup.4 represent hydrogen, halogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, C.sub.1-6 alkoxy, C.sub.1-4 alkyl substituted by a hydroxy or C.sub.1-4 alkoxy group, OCF.sub.3, hydroxy, trifluoromethyl, trimethylsilyl, nitro, CN, SR.sup.a, SOR.sup.a, SO.sub.2 R.sup.a, COR.sup.a, CO.sub.2 R.sup.a or CONR.sup.a R.sup.b, where R.sup.a and R.sup.b are each independently hydrogen or C.sub.1-4 alkyl; R.sup.2, R.sup.3 and R.sup.5 represent hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-4 alkoxy substituted by a C.sub.1-4 alkoxy group, or trifluoromethyl; R.sup.6 represents C.sub.1-6 alkyl, optionally substituted by oxo, substituted by a 5-membered heteroaromatic ring selected from oxazole, thiazole, isoxazole, isothiazole, oxadiazole and thiadiazole, wherein each heteroaromatic ring is substituted at the available carbon atom by a group of the formula: ZNR.sup.7 R.sup.8. The compounds are of particular use in the treatment of pain, inflammation, migraine and emesis.

    摘要翻译: PCT No.PCT / GB96 / 00587 Sec。 371日期:1997年9月16日 102(e)1997年9月16日PCT PCT 1996年3月13日PCT公布。 公开号WO96 / 29328 日期:1996年9月26日本发明涉及式(I)化合物,其中R 1和R 4表示氢,卤素,C 1-6烷基,C 2-6烯基,C 2-6炔基,C 3-7环烷基,C 3-7环烷基C 1-4烷基, C6烷氧基,被羟基或C1-4烷氧基取代的C1-4烷基,OCF3,羟基,三氟甲基,三甲基甲硅烷基,硝基,CN,SRa,SORa,SO2Ra,CORa,CO2Ra或CONRaRb,其中Ra和Rb各自独立地为氢或C1- 4个烷基; R2,R3和R5表示氢,卤素,C1-6烷基,被C1-4烷氧基取代的C1-4烷氧基或三氟甲基; R 6表示任选被氧代取代的,被选自恶唑,噻唑,异恶唑,异噻唑,恶二唑和噻二唑的5元杂芳环取代的C 1-6烷基,其中每个杂芳环在可用的碳原子上被一个式 :ZNR7R8。 该化合物特别用于治疗疼痛,炎症,偏头痛和呕吐。